Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163752 | 0.86 | SMN1; SMN2 (0.47) | POLBTSHRHPGDLMNATP53 | |
| SCHEMBL4154957 | 0.84 | SMN1; SMN2 (0.46) | MEN1KMT2APOLBTSHRHPGD | |
| SCHEMBL4157341 | 0.82 | MAPT (0.47) | MEN1KMT2AEPHX2TSHRHPGD | |
| SCHEMBL2186819 | 0.76 | POLB (0.51) | MEN1KMT2AHRH4POLBCYP2D6 | |
| SCHEMBL13504009 | 0.72 | SMN1; SMN2 (0.77) | MEN1KMT2AMAPK1CYP2D6CYP2C9 | |
| SCHEMBL13841322 | 0.72 | KDM4E (0.63) | MEN1KMT2AHRH4EPHX2MAPK1 | |
| SCHEMBL4163152 | 0.71 | HRH4 (0.53) | MEN1KMT2AHRH4EPHX2POLB | |
| SCHEMBL9364495 | 0.70 | EPHX2 (0.77) | MEN1KMT2AEPHX2POLBCYP2D6 | |
| SCHEMBL10399266 | 0.70 | HPGD (0.51) | KMT2AMAPK1POLBTSHRHPGD | |
| SCHEMBL17728836 | 0.70 | KMT2A (0.54) | MEN1KMT2AMAPK1POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| CN-1950375-A | Glucocorticoid receptor modulator compounds and methods- utility | LIGAND PHARM INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | MEN1 3261/4885KMT2A 4088/4885HRH4 285/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | MEN1 3261/4885KMT2A 4088/4885HRH4 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.